MOG Antibody Status Is Associated With Distinct Clinical Profiles and Treatment Responses in Chronic Relapsing Inflammatory Optic Neuropathy. (PubMed, Neurol Neuroimmunol Neuroinflamm) - Oct 25, 2026 - "CRION represents a heterogeneous syndrome encompassing distinct subgroups. Although MOG+ patients demonstrate higher disease activity, tocilizumab might represent a therapeutic option, though further validation is needed. Serologic testing is critical for treatment stratification and preventing relapses."
Journal • Retrospective data • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Solid Tumor • IL6
|
|
Achim Berthele; Anthony De Vere-Tyndall; Athina Papadopoulou; Corinna Trebst; Daria Tkachenko; Ilya Ayzenberg; Joachim Havla; Jonathan A Gernert; Katrin Giglhuber; Madalina Graure; Marina Herwerth; Marius Ringelstein; Martin Werner Hümmert; Michael Weller; Nathalie Nierobisch; Nuria Cerdá-Fuertes; Orhan Aktas; Patrick Roth; Rebecca Wicklein; Thivya Pakeerathan; Veronika Kana
|